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Abstract
Background: Anti-malarial regimens containing sulphonamide or artemisinin ingredients are widely used in
malaria-endemic countries. However, evidence of the incidence of adverse drug reactions (ADR) to these drugs is
limited, especially in Africa, and there is a complete absence of information on the economic burden such ADR
place on patients. This study aimed to document ADR incidence and associated household costs in three high
malaria transmission districts in rural Tanzania covered by demographic surveillance systems.
Methods: Active and passive surveillance methods were used to identify ADR from sulphadoxine-pyrimethamine
(SP) and artemisinin (AS) use. ADR were identified by trained clinicians at health facilities (passive surveillance) and
through cross-sectional household surveys (active surveillance). Potential cases were followed up at home, where a
complete history and physical examination was undertaken, and household cost data collected. Patients were
classified as having ‘possible’ or ‘probable’ ADR by a physician.
Results: A total of 95 suspected ADR were identified during a two-year period, of which 79 were traced, and 67
reported use of SP and/or AS prior to ADR onset. Thirty-four cases were classified as ‘probable’ and 33 as ‘possible’
ADRs. Most (53) cases were associated with SP monotherapy, 13 with the AS/SP combination (available in one of
the two areas only), and one with AS monotherapy. Annual ADR incidence per 100,000 exposures was estimated
based on ‘probable’ ADR only at 5.6 for AS/SP in combination, and 25.0 and 11.6 for SP monotherapy. Median ADR
treatment costs per episode ranged from US$2.23 for those making a single provider visit to US$146.93 for patients
with four visits. Seventy-three per cent of patients used out-of-pocket funds or sold part of their farm harvests to
pay for treatment, and 19% borrowed money.
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Conclusion: Both passive and active surveillance methods proved feasible methods for anti-malarial ADR
surveillance, with active surveillance being an important complement to facility-based surveillance, given the
widespread practice of self-medication. Household costs associated with ADR treatment were high and potentially
catastrophic. Efforts should be made to both improve pharmacovigilance across Africa and to identify strategies to
reduce the economic burden endured by households suffering from ADR.
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Background
The development of malaria parasite resistance to
commonly used drugs such as chloroquine and
sulphadoxine-pyrimethamine (SP) has complicated global
efforts to mitigate the burden of malaria disease especially
in the poorest countries [1,2]. The last decade has
witnessed major changes in malaria treatment protocols
with most malaria-endemic countries switching from
cheap and ineffective drugs to relatively expensive but
more efficacious artemisinin-based combination therapy
(ACT) [3,4]. ACT has been hailed by the World Health
Organization (WHO) as the best new hope for malaria
treatment in Africa and other endemic regions [5]. Until
the end of the 1990s, experience with large-scale use of
ACT was mainly confined in Southeast Asia [6]. At the
turn of the new century, larger scale ACT trials began
in other parts of the world including sub-Saharan Africa
[7,8]. By 2011, 79 countries and territories in malaria-
endemic regions had adopted ACT as first-line treatment
for Plasmodium falciparum malaria [9]. Meanwhile, SP
continues to be used as a drug of choice for intermittent
presumptive treatment for malaria in pregnancy (IPTp).
Nevertheless, sulphonamide medicines are widely used as
antibiotic regimens for acute respiratory infections, urinary
tract infections and as prophylaxis for HIV + patients
[10,11]. The use of sulphonamide-containing anti-malarials
and other anti-malarial drugs with artemisinin ingredients
has in the last decade become widespread [12].
Adverse drug reactions (ADR) can be defined as
any drug action that is not of diagnostic, therapeutic
or prophylactic benefit to the user [13]. To date, most
studies documenting the incidence of ADR caused by
sulphonamides have been outside Africa [14-17].
Sulphonamide-containing anti-malarials have been
found to cause severe adverse reactions, including se-
vere skin rash (toxic epidermal necrolysis (TEN) and
Stevens-Johnson syndrome (SJS)), liver disorders, and
bone marrow suppression [15]. Furthermore, the
spread of HIV infection is thought to have increased
the number of patients experiencing sulpha-related
reactions because of multiple drug use in the context
of a compromised immune system [18,19]. Conflicting
results associating overdose of artemisinin containing
drugs with unusual and selective patterns of damage
to certain brainstem nuclei in animals and humans
have also been reported [20-23].
Concerns about the incidence of ADR in sub-Saharan
Africa have increased for a number of reasons. First, there
is widespread self-medication and presumptive treatment
of malaria, which tends to lead to over- prescription of
anti-malarials for febrile illnesses. Second, there are con-
cerns about proliferation of substandard and counterfeit
medicines, exacerbated by weak national regulatory author-
ities [24-26]. The third reason relates to increasing numbers
of new anti-malarials entering the market in the context of
an almost complete lack of phase IV post-marketing
surveillance in the region [27,28].
Because of these concerns, public health researchers
and policy makers are supporting efforts to establish
effective and reliable drug surveillance programmes in
Africa [27-29]. However, only a few studies have investi-
gated the frequency of anti-malarial ADR in sub Saharan
Africa [30-32]. This study aims to address this gap. It is a
component of the Interdisciplinary Monitoring Programme
for Anti-malarial Combination Therapy (IMPACT-Tz)
which was jointly designed and implemented by the Ifakara
Health Institute (IHI) and the US Centers for Disease
Control and Prevention (CDC) in collaboration with the
Government of Tanzania [33]. The study implemented both
passive and active ADR surveillance systems in health and
demographic surveillance sites (HDSS) covering parts of
the three districts of Rufiji, Kilombero and Ulanga [34]. The
HDSS sites cover a combined population of over 157,000,
roughly about 22% of the total population residing in the
three districts (estimated at 716,892 in 2002) [35]. Three
times a year, HDSS staff visit households sampled from a
cluster of 56 enumerated villages to collect data on health,
demographic and socio-economic indicators.
The aim of the ADR surveillance system was to docu-
ment both household-level incidence and economic burden
of ADR resulting from use of anti-malarials. The study used
community and health facility-based surveillance to register
and follow up all potential ADR resulting from use of
sulphonamide- and artemisinin-containing anti-malarials.
This investigation covered over 157,000 individuals and
successfully completed 24 months of clinical surveillance
on ADR events caused by use of SP and/or AS anti-
malarials in moderate to high transmission settings in rural
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Tanzania. Additionally the study provides the first data on
the cost burden incurred by households in treatment of
patients with anti-malarial ADR. This information has two
key uses: first, it should help prioritize pharmacovigilance
activities and the provision of services to ADR sufferers;
and secondly, these cost estimates can contribute to large
cost-effectiveness analyses of, for example, changing
national drug policy as well as providing more accurate
and complete estimates of the household economic
burden of malaria.
Methods
Description of the study sites
This study was part of a multi-year project involving evalu-
ation of large-scale use of anti-malarial combination drugs
implemented in three rural districts of Kilombero, Ulanga,
and Rufiji located in Morogoro and Coastal Regions in
south-eastern Tanzania. The project is described in detail
elsewhere [36,37]. The districts are geographically contigu-
ous, but the Rufiji population is separated from those of
Kilombero and Ulanga by the Selous Game Reserve. The
most common occupation in the study areas is subsistence
farming, with rice, maize and cassava being predominant
food crops. Other economic activities include animal hus-
bandry, fishing and small-scale trading. The districts have
very limited paved roads and some villages are cut off from
major market centres during rainy seasons. At the time this
study was being conducted, malaria transmission was year
round intense with very high estimated mean entomo-
logical inoculation rate of between 79 and 1,209 infective
bites per person per year [38]. Malaria remains the leading
cause of outpatient diagnoses, and reported inpatient deaths.
Health care is provided by a network of public and faith-
based health facilities, including hospitals, health centres
and dispensaries, but a significant portion of care is also
provided by private sources, predominately drug shops and
kiosks [39]. Moreover, studies have shown that up to 40%
of patients seek care from private sources [37,40].
In Tanzania, anti-malarial treatment policy was changed
in August 2001 when chloroquine was replaced with SP as
first-line drug for uncomplicated P. falciparum malaria.
By this time chloroquine treatment failures had reached a
record level of over 60% of all outpatient malaria cases
[41]. The switch to SP led to widespread public concern
due to fear of ADR, which was extensively covered in the
media, leading many people to avoid SP use [42]. From
2003 through 2006 the IMPACT-Tz project piloted
district-wide ACT use in Rufiji, using the combination of
SP + artesunate (SP/AS). As evidence of increasing SP
clinical failures accumulated, the national first-line policy
was changed again after only five years, with the ACT
artemether-lumefantrine (ALu) being nationally adopted
as first-line drug in 2006 [43]. To accomplish this study,
data collection was carried out during the year 2003 to
2005. Therefore, during the period of data collection for
this study, the first-line anti-malarial was SP monotherapy
in Kilombero and Ulanga, and AS/SP in Rufiji. For this
reason, the ADR surveillance findings are presented
separately for Rufiji District. During the same period,
approximately 58% of patients with febrile illnesses
were given anti-malarials upon their visit to health facilities
or drug outlets.
Data collection
ADR cases were identified through both passive and
active surveillance. For the passive surveillance system
from February 2003 clinical personnel in public and
faith-based health facilities in the HDSS were trained on
the signs and causes of ADR reactions. At least one
health worker from a network of one hospital, four
health centres and 28 dispensaries was trained to recognize,
treat, document and report ADR cases presenting at their
health facilities. The majority of trained health practitioners
were clinical officers and nurses, with a few general
physicians. Colour photographs of patients with SJS/TEN
were provided and potential ADR were discussed in detail.
A screening case definition for suspected severe
cutaneous ADR was defined as having at least two of
the following symptoms: (i) a widespread, disseminated
rash, (ii) blisters or skin detachment greater than 3 cm in
diameter, or (iii) lesions on at least one mucous membrane.
Additionally, clinicians were instructed to report all patients
suffering from ataxia, impaired fine finger dexterity, balance
problems, facial oedema, shortness of breath, urticarial
rashes, or if the patient felt lightheaded within 30 min of
taking the medication. Moreover, following active surveil-
lance implementation (see below), additional symptoms of
vomiting, stomach ache, diarrhoea and headache were
added to the standard protocol definition after these were
reported on multiple case follow-up visits.
Clinicians were asked to document clinical and
demographic information of patients presenting with
ADR symptoms on standard Tanzania Food and Drug
Authority (TFDA) adverse event reporting forms and
in specially provided log books. These reports were
forwarded to the District Health Management Teams
(DHMTs) and the Project ADR Surveillance Officer
(ADR SO) for follow-up investigation. All ADR SOs
were medical professionals with background in clinical
training as clinical officers and/or assistant medical officers.
Standard screening procedure based on review of ADR
clinical literature and the expert advice from SJS derma-
tologist was developed and adopted for training the ADR
SOs to assess and categorize ADR events. Additionally, a
set of standard questions based on many years of field data
collection experience in this area, were jointly developed
by IHI and CDC Malaria Branch researchers to help
clinicians ascertain any additional side-effects not captured
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in the standard protocol. The ADR SO conducted a
complete history and physical examination of each patient
with particular attention on the drug-use history and
dermatologic examination. In the event of fatalities, the
parent or caretaker of the patient was interviewed. This
study reports on ADR events detected through passive
surveillance, from January 2004 to December 2005.
To increase the number of cases reported, passive
surveillance was supplemented by active case detection
in 2004 and 2005. Questions on uptake of anti-malarials,
particularly SP and/or AS, in the past 90 days and any
related side effects were asked through cross-sectional
household surveys completed in 2004 and 2005. The
surveys were conducted from June to September of each
year, capturing the typical high malaria transmission season
in the study area. For each year’s survey, independent
samples from the same clusters of 56 census enumerated
villages (31 in Rufiji and 25 in Kilombero/Ulanga)
were randomly selected [37]. Following informed consent,
questionnaires were administered to a total of 16,290
individuals from over 5,300 households in the two
years combined. Of those interviewed, 46.5% were
from Rufiji and the remaining 53.5% were from
Kilombero/Ulanga. Respondents were asked whether
they, or their children, experienced specified side effects
defined in the study protocol following their SP and/or AS
intake during the last three months. Respondents were also
asked to list other side effects/experiences related to these
drugs. The ADR SO reviewed the completed questionnaires
and selected all potential ADR cases for detailed clinical
examination. Each suspected ADR case reported through
active surveillance was visited at home by the ADR SO after
the completion of each round of the household survey. As
with cases identified through passive surveillance, the ADR
SO conducted a detailed history and physical examination
of ADR patients and interviewed the patient or their
caretaker/close relatives. To avoid double counting by
active and passive surveillance systems, the ADR SOs
contacted clinicians at local health facilities to harmonize
their information.
All completed case follow-up reports were forwarded
to study physicians who classified the suspected cases
into one of five categories: i) probable or ii) possible
severe adverse reaction (TEN/SJS and/or severe neuro-
logical reaction and/or anaphylaxis) associated with
sulphonamide and/or artesunate intake; iii) probable or
iv) possible severe adverse reaction (TEN/SJS and/or
severe neurological reaction and/or anaphylaxis) not
associated with sulphonamide and/or artesunate intake; or
(v) skin condition, neurological reaction and/or anaphylactic
reaction not consistent with an expected side effect
from sulphonamide-containing anti-malarial and/or
artesunate drug intake. Side effects like headaches,
diarrhoea and nausea that did not occur concurrently
with the ADR symptoms (i.e. skin conditions including
lesions and blisters) were not included in the ADR inci-
dence calculations but their related household treatment
costs were accounted because of their economic signifi-
cance. A patient was considered exposed if s/he reported
any use of SP and/or AS in the 30 days before initial
symptoms of drug reactions were observed.
The interviews for all suspected ADR cases identified
included questions on care-seeking and household treat-
ment costs. Household cost data collected covered both
health facility based expenditures (drugs, registration/
consultation, inpatient admission, laboratory test expenses,
informal payments), and non-facility expenditures (travel
costs, food and accommodation costs for patients and those
accompanying them to providers). Respondents incurring
cash expenditures were asked how these expenses were
paid for. The study did not attempt to estimate the indirect
productivity costs in terms of working days lost for patients
and caretakers.
Estimation of ADR occurrence rates
To obtain the numerators for calculation of ADR
occurrence rates due to exposure to SP and/or AS,
events meeting the physicians’ classification of ‘probable’
ADR cases were included (‘possible’ ADR were not
included in incidence estimates). For the denominator, the
proportions of the population exposed to sulphonamide
and artemisinin-based anti-malarial drugs was obtained
through the household surveys in 2004 and 2005 described
above, together with similar surveys conducted in 2001 and
2002, to help capture the variations of malaria prevalence
in the study area. In these cross-sectional surveys,
individuals within households were asked about their
use of sulphonamide-containing anti-malarials in the
past two weeks. The two weeks reported anti-malarial
use was multiplied by 26 to ascertain their annual
usage rates. Annualized SP and/or AS exposure rates
were extrapolated for the entire HDSS study sites
populations expressed as proportion of ADR occurrence
per 100,000 exposures.
Data management and analysis
Data were double entered in FOXPRO 2.6a (Microsoft
Inc, Redmond, WA, USA), and analysis was performed
using STATA version 10 (Stata Corp, College Station,
TX, USA). Costs are presented in 2005 US$ (exchange
rate US$1 = TZS1,150/=)[44].
Ethical clearance
This study received ethical approval from the institutional
review boards of the Ifakara Health Institute, the
Tanzanian Medical Research Coordinating Committee
and the US Centers for Disease Control and Prevention.
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Results
Suspected ADR cases recorded through active and
passive surveillance
A total of 95 suspected ADR cases were identified
during the two year period (Table 1). Of these, 44 cases
were recorded through passive surveillance and 51
through active surveillance. Of the reported cases, 71
(74.7%) were patients aged over five years, and 58 (60%)
were women. Fifty (52.6%) of these events were recorded
in Kilombero/Ulanga. A total of 79 (83.2%) cases were
successfully traced for further clinical examination and
ADR classification. Sixteen of the 95 cases, nine in
Kilombero/Ulanga and seven in Rufiji could not be
traced because of relocation, poor road accessibility and/
or incorrect recording of patients’ residential information.
After reviewing all traced case reports from the ADR SO,
the project physician classified the events as follows: 67
(84.8%) were related to intake of SP and/or AS; eight
(10.1%) cases were excluded because they occurred outside
the HDSS area or were recorded before January 2004; and
four (5.0%) were inconsistent with SP and/or AS intake.
The physician further classified the 67 cases associated
with SP and/or AS as ‘probable’ or ‘possible’ADR cases. A
total of 34 (51%) cases were certified as ‘probable’ events
and the remaining 33 (49%) as ‘possible’ (Table 2). The
majority of “probable” cases (n = 29) were associated with
SP monotherapy intake, with only five cases associated with
the AS/SP combination, and none with AS monotherapy.
Fourteen of the probable events were recorded in Rufiji
where AS/SP combination drugs were being piloted, and
the remaining 20 were recorded in Kilombero/Ulanga
where AS was not provided. For the 33 cases classified as
‘possible’ ADR events, 24 were associated with use of SP
monotherapy, eight with AS/SP intake, and only one with
AS monotherapy.
About 78% of patients or caretakers interviewed
reported experiencing/seeing multiple ADR symptoms
within 36 hours of SP and/or AS intake. The dominant
illness conditions reported by the 67 patients included
a combination of one or multiple illness diagnostic
conditions such as; body blisters and skin detachment,
body swelling, itching and urticarial rashes, multiple
lesions on mucous membranes around the mouths,
nose or conjunctivae, and facial oedema, and other
side effects like light-headedness, headache, shortness
of breath, stomach ache, diarrhoea, vomiting, and also
severe kidney pain (Table 1).
Four patients died at health facilities following clinical
deterioration within three weeks following onset of drug
reactions associated with SP use. A further three patients
died outside health facilities with reported treatment of
drug reactions prior to their deaths. Four of the
deceased had reported SP intake, two had used the AS/SP
combination and one had used sulphonamide-containing
antibiotics to treat other illnesses. Two of the victims were
reported to have had swollen bodies and blisters, including
mouth, nose and ear membrane lesions. Other fatalities
suffered multiple complications including kidney failures
Table 1 Adverse drug reactions reported through active and passive surveillance and dominant symptoms reported
Rufiji District Kilombero/Ulanga Districts1 Total (%)
Total suspected adverse drug events reported 45 50 95 (100)
Identified through active surveillance 21 30 51 (53.7)
Identified through passive surveillance 24 20 44 (46.3)
Number of cases successfully traced 38 41 79 (83.2)
Of the successfully traced cases: 38 41 N = 79 (100)
Events associated with SP monotherapy 20 33 53 (67.1)
Events associated with AS/SP combination therapy 13 0 13 (16.5)
Events associated with AS monotherapy 1 0 1 (1.3)
Events outside DSS area (excluded) 3 5 8 (10.0)
Events unrelated to SP and/or AS (excluded) 1 3 4 (5.0)
Dominant symptoms reported for those included: 34 33 N = 67 (100)
Body blisters and skin detachment 7 11 18 (26.9)
Body swelling, itching and urticarial rashes 10 6 16 (23.9)
Multiple lésions on mucus membranes 6 7 13 (19.4)
Facial edema, sore mouth/nose conjunctiva 5 4 9 (13.4)
Others1 6 5 11 (16.4)
Deaths
Deaths attributable to SP and/or AS caused ADR 2 4 6 (8.9%)
1. These include side effects such as headache, lightheadedness, shortness of breath, stomachache, diarrhoea, vomiting and kidney pain.
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(n = 3), with one case exhibiting pneumonia-like
symptoms. All reported deaths were classified as ‘probable’
ADR events.
Estimation of ADR occurrence rate
ADR rate of occurrence was estimated from the 34 cases
classified as ‘probable’ ADR events due to exposure to SP
and/or AS (Table 3). Following the nine probable ADR
events resulting from use of SP monotherapy in Rufiji
HDSS, annual ADR occurrence rate per 100,000 exposures
per year was estimated at 11.6 events for the Rufiji HDSS
population. Annual ADR occurrence rate of 5.6 cases per
every 100,000 exposures to AS/SP combination drugs used
was estimated for the same population and there were no
ADR cases due to AS monotherapy in Rufiji. In Kilombero
and Ulanga HDSS, SP monotherapy was estimated to
cause 25 ADR cases per 100,000 exposures per year
(no use of AS or AS/SP combination therapy was
reported in Kilombero/Ulanga).
Care-seeking patterns
Complete costing information was available for 50 (74.6%)
of the 67 cases classified as ‘possible or probable’ ADR
associated with SP and/or AS. Seventeen cases were
excluded in the final household cost analysis due to failure
to provide complete treatment costing information; ten
were unable to recall any of the expenses incurred and the
remaining seven had incomplete cost information. Since
both cases classified as ‘probable’ or ‘possible’ADR events
had incurred some costs during treatment, they were all
included in the cost analysis. Table 4 summarizes the
characteristics of these ADR patients and their treatment-
seeking behaviour. Of all 50 patients with complete cost
information, 37 patients incurred some expenses. Twenty-
three patients financed their costs through out of pocket
expenditures, with only three cases paying through
community-based or government-employee insurance
schemes. Five ADR patients reported having made
informal payments at the place they sought care; mainly at
government health facilities.
Forty-five patients reported visiting government or private
health facilities, three obtained drugs from private
drug outlets only and two obtained drugs from relatives
and friends. Of those visiting healthcare providers, patients
made one to four visits to single or different providers. A
total of 77 visits to different healthcare providers
were made. The majority (44 (57%)) were to public
health facilities, mainly government dispensaries and
Table 2 Classification of adverse drug reactions by type
of surveillance, site and type of drugs used
Probable Possible TOTAL
Type of Surveillance
Passive surveillance 25 18 43
Active surveillance 9 15 24
Study District
Rufiji 14 20 34
Kilombero/Ulanga 20 13 33
Type of Drug Used
SP monotherapy 29 24 53
AS monotherapy 0 1 1
AS/SP combination 5 8 13
TOTAL 34 (51%) 33 (49%) 67 (100%)
Table 3 Parameters for estimation of ADR incidence from






Probable ADR events detected by passive surveillance:
SP monotherapy 7 13
Artesunate monotherapy 0 0
Combination of AS/SP 3 0
Total 10 13
Probable ADR events detected by active surveillance:
SP monotherapy 2 7
Artesunate monotherapy 0 0
Combination of AS/SP 2 0
Total 4 7
Total probable ADR events detected:
SP monotherapy 9 20
Artesunate monotherapy 0 0
Combination of AS/SP 5 0
Total 14 20
Total Population Under DSS
Surveillance
84,500 74,200
Estimates of average annual anti-malarial drug exposure rates in
the DSS areas per capita:
SP monotherapy 0.46 0.54
Artesnuate monotherapy 0.37 0
Combination of AS/SP 0.53 0
Estimate of total doses used by the DSS population in 2004/5
(population * average annual exposure)
SP monotherapy 38,870 40,068
AS monotherapy 31,265 0
Combination of AS/SP 44,785 0
Estimated ADR incidence per 100,000 exposures1
SP monotherapy 11.6 25.0
AS monotherapy 0 -
Combination of AS/SP 5.6 -
1Calculated as (Number of “probable” ADR cases / estimated total doses used)
* 0.5 (multiplied by 0.5 to annualize ADR occurrence rates since our data cover
a two year period).
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health centres, followed by 24 (31%) to faith-based and
NGO facilities, with only seven (9%) to commercial retail
drug stores. There were two (3%) patients who obtained
drugs from their relatives and friends only. Furthermore,
two patients made four visits each, three patients made
three visits, 15 made two visits, and the remaining 30
patients sought care from one provider. Reasons given for
multiple visits included poor case diagnosis, slow recovery
and lack of appropriate drugs or drug stock-outs. For the
two patients making four visits, one patient made two
visits to a government dispensary, one visit to a mission
dispensary, one visit to a disability hospital in Dar es
Salaam and a government district hospital in Rufiji
District. The other visited a drug shop, a government
dispensary, a government health centre and finally a
mission hospital.
Of all 50 ADR patients with complete cost information,
22 (44%) were admitted at some point during the illness
episode, with admissions lasting from 24 hours up to
60 days. The mean number of admission days was 14.5
(SD-17.12) with a median of 7.5 days and an interquartile
range (IQR) of 13 days.
Household costs of treatment-seeking
Total household costs per episode are shown in Table 5
including those with and without expenditure, and those
having fully recovered, partially recovered or died. Mean
expenditure per episode was US$24.15 (SD 40.00) with a
median of US$10.00 and a range from US$0 to 226.04. If
only those who reported some expenditure are included,
the mean outlay per episode was US$31.78 (SD 43.18),
with a range of US$0.22 to 226.04 and a median of
US$19.59. Considering all cases, there was some variation
in expenditure by patient characteristics (though results
should be interpreted with caution given the small
sample size). Median expenditure was significantly
higher for ‘probable’ ADR events compared to ‘possible’
ADR (p = 0.079), for admitted cases compared to those
managed as outpatients (p = 0.000), and for cases which had
taken SP alone compared to SP + artesunate (p = 0.013), but
there were not corresponding significant changes in mean
expenditure. Mean and median costs were significantly
higher for patients who made multiple provider visits
(T-test for the means and Mann–Whitney median
test of p < 0.001 and p = 0.016, respectively for those
Table 4 Patient characteristics, care-seeking and type of payments: (Includes all probable and possible cases with
complete cost information)
Rufiji District Kilombero/Ulanga Districts Total
Number of cases with complete cost information 28 22 50
Health outcomes on day of interview:
Fully recovered 21 17 38
Partially-recovered 3 2 5
Patients died 4 3 7
Patient characteristics:
Female 17 13 30
Age under-five years 6 6 12
Patient care-seeking sources:
Public health facilities 19 12 31
Faith based/NGO facilities 6 8 14
Private drug shop outlets 2 1 3
Obtained drugs from family & neighbours 1 1 2
Treatment expenditure pattern
Patients with no expenses 11 2 13
Patients with one or multiple expenses 17 20 37
Payment mechanisms for patients with treatment expenses N = 37
Only cash that was to hand/past savings 10 13 23
Health insurance (community/employer) 1 2 3
Cash to hand and/or selling household assets or part of farm harvest 1 3 4
Borrowed from friends or relatives 5 2 7
Report of any informal payments
Made informal payments at the place of care 2 3 5
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making single visit compared to four visits). Finally, the
mean expenditure per visit was US$15.68 (SD 20.56) with
a median of US$8.18.
Moreover, ADR treatment expenditure by type of health
care providers visited was explored. Overall, faith-based
and NGO facilities were the most expensive with median
expenditure of US$22.41 per visit, followed by private
drug retailers at US$15.40, and government health
facilities (median of US$5.56) (Table 6). There was a
significant difference between both mean and median
expenditures at government health facilities and faith-based/
NGO facilities (T-test for the means: p = 0.0160 and
Mann–Whitney median test: p = 0.0002).
Drug costs constituted the largest component of total
treatment expenditures at 43.3%, followed by transport,
food and accommodation (32.9%), and registration,
consultation, laboratory tests and other fees (23.8%)
(data not shown). In one case the family of a deceased
patient reported hiring a vehicle to transport the patient
from Dar es Salaam to Rufiji District costing them about
US$130. The expenditure pattern was fairly similar for
both government and non-governmental facilities, with
expenditure at private drug retailers being mostly on
drugs alone. For those reporting informal expenses, pay-
ments ranged from US$0.21 to 4.34 per visit, with a mean
informal payment of US$1.07 and median of US$0.36.
For the four patients reporting to have sold some of
their assets or farm harvests, they mentioned selling
various items including animals, bags of rice and corn and
household furniture. Additionally, seven had to borrow
from relatives or friends to pay their treatment bills.
Discussion
ADR occurrence rates in rural Tanzania were estimated
at 11.6 and 25.0 due to exposure to SP in Rufiji and
Kilombero/Ulanga respectively. Incidence due to use of
Table 5 Household treatment expenditure per ADR episode (2005 USD)
Expenses for patients with and without expenditures
Number of episodes Mean* Median# Range
Episodes with complete cost information (with and without expenses) 50 24.15 10 0.00 – 226.04
ADR Classification:
Probable 31 28.85 14.61~ 0.00 –226.04
Possible 19 16.48 3.48~ 0.00 – 115.91
Treatment costs by admission status:
Admitted 22 47.18** 30.83** 0.00 – 226.04
Not admitted 28 6.05** 2.61** 0.00 – 35.39
Treatment costs by survivorship
Costs for patients surviving 43 17.15 7.80^ 0.00 – 125.87
Costs for Patients dying 7 63.89 28.74^ 0.00 – 226.04
Number of visits:
One 30 7.24** 2.23^ 0.00 – 44.04
Two 15 32.01** 28.74^ 1.74 – 115.91
Three 3 72.09 46.48 43.91 – 125.87
Four 2 146.93** 146.93^ 67.83 – 226.04
Study district:
Rufiji 28 21.68 3.61^ 0.00 – 226.04
Kilombero / Ulanga 22 27.29 21.80^ 0.00 – 115.91
Age group:
Under 5 years 13 11.60 5.99 0 – 32.91
5 years or over 37 28.11 10.78 0 – 226.04
By drug use
AS only 1 9.74 9.74^ 9.74 – 9.74
SP only 35 29.02 19.61^ 0 – 226.04
SP + Artesunate 14 13.00 3.61^ 0 – 125.87
Note: *Students t-test between groups & #Wilcoxon rank sum (Mann- Whitney) test.
**Significant between one and four visits, and between two and four visits at 1% level.
^Significant between groups and/or between one and four visits and between two and four visits at 5% level.
~Significant between groups and/or between one and four visits, and between two and four visits at 10% level.
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AS/SP combination was substantially lower at 5.6 per
100,000 exposures. A number of reasons might have
been responsible for this trend, including differences in
quality of care, frequency of drug use between the sites
and a relatively sporadic supply chain for the AS/SP
combination drugs. At least in Kilombero and Ulanga
district, there was a project engaged in improving access
to anti-malarials which might have also influenced the
use of sulphonamide containing anti-malarials amongst
the targeted population [45]. Our study design may also
have been somehow biased as it was more geared to
identify ADR cases caused by use of SP monotherapy
than AS/SP combination drugs. Following the national
anti-malarial policy change, there were anecdotal reports
of ADR events caused by SP drugs resulting to general
public outcry and resistance in using SP drugs for malaria
treatment. Therefore, ADR SOs in districts with SP mono-
therapy enjoyed closer supervision and follow-up of their
activities than those in Rufiji which includes the highly
inaccessible Rufiji delta area where reporting and tracing
cases for confirmation might have been more difficult.
Seven of the 67 cases successfully traced and clinically
classified died for reasons associated with ADR. Of those
dying, four were recorded in Rufiji and three were from
Kilombero and Ulanga districts. Estimations of ADR
occurrence rates were based on cases classified as ‘probable’
ADR events only, and would have been higher if ‘possible’
ADR had also been included. It is also important to note
that most of the ADR cases reported were associated with
SP and SP/AS (but none for AS alone).
These findings may be compared with studies conducted
in other malaria-endemic settings including Malaysia, Peru
and Malawi [16,17,30]. In the Malaysian study, ADR
incidence was estimated at 2.4 per 100,000 exposures
to SP. SP was used prophylactically by almost a half
of those exposed and almost certainly involved repeated
dosing [17]. The study in Peru followed up patients exposed
to the combination of SP plus artesunate in selected clinics
for two years, with 8% reporting some associated ADR,
although very mild reactions were included in the ADR
definition [16]. A study in Blantyre, Malawi beginning early
2001 used a definition more comparable to that used in this
study, and estimated ADR associated with use of SP or
trimethoprim-sulphamethoxazole (cotrimoxazole) at 0.3 to
8.4 per 100,000 exposures [30]. ADR incidence among HIV
positive persons was higher at 20.4 per 100,000 exposures.
This study did not collect information on HIV status during
the IMPACT-Tz study, however, other sources indicate that
HIV prevalence rates at the time ranged from 4 to 7%
across the study districts [46]. The studies from Peru and
Malawi relied on health facility-based surveillance only,
with no active community surveillance. The authors of the
Malawi study in particular acknowledged this limitation
and suggested that that the number of ADR cases might
have been under-reported, especially in areas where access
to health facilities was difficult [30]. Following the nature of
active surveillance component of this study, it is not
surprising that incidence rates are higher. Studies on
healthcare-seeking behaviour in the three study districts
have reported that government health facilities see less
than 60% of all healthcare seekers with fever/malaria, with
many patients purchasing drugs at drug shops, general
shops and small kiosks [40,47], an indication that reliance
on passive surveillance only is likely to miss some cases.
However, it is possible that the figures presented in this
study are underestimated, as recall bias and the assumption
of homogeneity in the level of exposure to these drugs may
have led to under-reporting during active surveillance,
especially of more minor ADR. It is also important to note
that this study’s surveillance estimates were based on areas
with routine demographic surveillance where a range of
health interventions are continually evaluated. It is possible
that exposure to anti-malarial drugs in the study sites was
therefore higher than might be reported from the rest of
the country.
Analysis of the household costs of treating probable and
possible ADR events resulting from use of anti-malarials
showed that despite these events being rare occurrences,
their associated treatment expenses can have important
economic consequences. Mean treatment expenditure for
an ADR episode was US$24.45 with a median of US$10.00,
with average expenditure rising rapidly with number of
providers visited. Average household costs of care
were ten-fold higher than those reported for treating
an episode of fever or malaria [48,49]. For example,
studies conducted in the same districts in mid-2001
Table 6 Household treatment expenditure per visit by provider type (2005 USD)1
Source of care visited Number of visits Mean Median Range
Government facilities 44 11.79* 5.56^ 0 – 87.74
Faith based and NGO facilities 24 24.71* 22.41^ 0.09 – 81.04
Private drug outlets 7 13.68 15.4 0.56 – 33.83
Drugs from relatives and friends 2 0 0 0.00 – 0.00
All patients visits1 77 15.68 8.18 0 – 87.74
1 Includes those with and without any expenditure.
* Student t-test significant at 1% level between Government and Faith based /NGO Health Facilities.
^ Mann–Whitney test significant between the two groups at 5% level: Government vs. Faith based / NGO Health Facilities.
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reported a mean household expenditure of US$0.30
and a median of US$0.06 (all in 2001 prices) per
fever episodes [50].
Furthermore, some patients with ADR endured lengthy
periods of illness as indicated by median admission days
of 7.5 with the longest hospital admission lasting 60 days.
Data were not collected on the total number of disability
days caused by ADR events, but it seems likely that the
number of productive days lost was higher than those
usually reported in most malaria studies which do not
consider ADR [48,49]. By the time this study was com-
pleted, of the 50 patients with complete cost information,
five (10%) patients said they were yet to fully recover.
The costs for treating ADR resulting from use of SP
monotherapy were found to be higher than those from
ACT use. However, this may be confounded by the different
health financing policies in place in the two study areas
during the study period. In Kilombero and Ulanga Districts
where SP monotherapy was routinely delivered as first-line
treatment, government facilities had started implementing
user fees for all patients except pregnant mothers and
children aged below five years in early 2003. In contrast, in
Rufiji District, where SP/AS was available, services at
government-owned facilities were officially free until late
2005 when user fees were introduced for the first time.
There are indications that the costs associated with
treatment of drug reactions placed substantial financial
burden on the households concerned. Of the 37 ADR
patients who paid money while seeking treatment, only six
patients made payments through a health insurance
scheme, an indication of very low health insurance coverage
in these areas. Additionally, eight patients reported having
to sell part of their farm harvests or household assets; and
two had to borrow money to finance their treatment. An
alternative way to understand the magnitude of the
treatment burden placed on households because of
ADR events is by comparison with total household
per capita income or expenditure. Tanzania’s GDP per
capita was estimated at US$326 in 2005 [51], and median
monthly household expenditure in the HDSS study sites
ranged from US$77 to 96 with 75% of expenditure on
food [34]. Following the WHO criteria for catastrophic
expenditures, households spending 50% or more of
their non-food expenditure on healthcare are likely to
be impoverished by the cost [52,53]. Other studies
have defined household expenditures as catastrophic
whenever household healthcare spending exceeds 40%
of income remaining after subsistence needs are met
[54,55]. In either case, these findings indicate that a
majority of treatment expenditures on adverse events
could be considered catastrophic.
Finally, it is important to note that full cost information
was only available for 50 patients classified as ‘possible or
probable’ ADR events. This is an inherent problem with
studying rare events. Some respondents had to recall
costs over a relatively long period compared to standard
household surveys, which may have increased the likelihood
of recall bias. However, perhaps reflecting the fact that ADR
are unusual and possibly catastrophic events, during data
collection interviewees did not have difficulties in remem-
bering treatment sought and costs incurred. Meanwhile it is
also important to note that five cases included in the
costing analysis had not fully recovered on the day of
interview. This may have slightly underestimated the
total cost of their treatment. However, all except one
had already obtained all their drugs for treating their
conditions and were unlikely to visit healthcare facilities
or drug shops for additional treatment to the same illness.
While these drugs were found to be generally safe, this
study underscores the importance of improving ADR
surveillance for anti-malarial drugs. The use of active
surveillance especially in places with HDSS research
platforms may play an important part in enhancing post
marketing drug safety surveillance. Efforts to increase
access to effective anti-malarials should go hand in hand
with implementation of effective drug safety surveillance
across nations [28], especially given the new generation
of anti-malarial drugs in the pipeline and concerns about
fake and substandard anti-malarials [26,56].
Conclusions
Household ADR occurrence rates in rural Tanzania were
estimated at 11.6 and 25.0 per 100,000 exposures to SP
in Rufiji and Kilombero/Ulanga Districts respectively,
and at 5.6 per 100,000 exposures to AS/SP in Rufiji.
Both passive and active surveillance methods proved
to be feasible for carrying out SP and/or AS related
ADR surveillance. Active surveillance provided an
important complement to the health facility-based
passive surveillance, given the widespread practice of
self-medication in Tanzania. The costs of treating
patients suffering from ADR were high and potentially
catastrophic to the majority of poor households, with
particularly high costs for those reporting hospital
admissions. Efforts should be made to both strengthen
pharmacovigilance monitoring across Africa and to
identify strategies to reduce the economic burden for
households suffering from ADR.
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